1,106 material Form 8-K filings that 909 companies we cover made with the SEC in June 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Worthington Enterprises reported fiscal 2026 fourth-quarter net sales of $371.5 million, up 17%, and GAAP diluted EPS of $0.97 versus $0.08 a year earlier, a period that included a $50.8 million impairment. Adjusted diluted EPS fell to $0.97 from $1.06, while full-year net sales rose 20% to $1.4 billion and adjusted diluted EPS rose to $3.37 from $3.09. The company also declared a $0.20 quarterly dividend and appointed W. Bradley Southern as a director.
Q4 net sales $371.5 million, up 17%; GAAP diluted EPS $0.97 vs $0.08; adjusted diluted EPS $0.97 vs $1.06
Full-year net sales $1.4 billion, up 20%; GAAP diluted EPS $3.14 vs $1.92; adjusted diluted EPS $3.37 vs $3.09
Quarterly dividend of $0.20 per share, payable September 29, 2026, to holders of record on September 15, 2026
Former Louisiana-Pacific CEO W. Bradley Southern appointed director; board plans to reduce authorized directors to 11 as three directors retire
FedEx reported fiscal fourth-quarter revenue of $25.0 billion, up from $22.2 billion a year earlier, and adjusted diluted EPS of $6.31, up from $6.07. GAAP diluted EPS fell to $6.60 from $6.88, mainly due to FedEx Freight spin-off costs, business optimization costs and other adjustments. The filing also completed the June 1, 2026 FedEx Freight spin-off and gave a calendar 2026 outlook of about 11% revenue growth and GAAP diluted EPS of $16.55 to $17.75.
Q4 revenue $25.0 billion vs. $22.2 billion a year earlier; GAAP operating income $1.55 billion vs. $1.79 billion
Q4 adjusted diluted EPS $6.31 vs. $6.07; GAAP diluted EPS $6.60 vs. $6.88
Calendar 2026 forecast: revenue growth about 11%, GAAP diluted EPS $16.55 to $17.75, adjusted $16.90 to $18.10; plans to repurchase up to $1 billion of shares
Boundless Bio agreed on June 22, 2026 to an all-stock merger with privately held Serapha Bio, a clinical-stage company developing an in vivo base editing therapy for Alpha-1 Antitrypsin Deficiency. Boundless stockholders are expected to own about 3.69% of the combined company, and the company's CEO, Zachary Hornby, steps down effective July 1, 2026, which affects shareholders' stake and the company's management.
Merger agreement dated June 22, 2026; the combined company is expected to operate as Serapha Bio and trade as AATD, subject to Nasdaq approval
Pre-merger Boundless holders expected to own about 3.69% and Serapha holders about 96.31% of the combined company, fully diluted
Boundless may pay a pre-closing cash dividend; the press release says about $44 to $48 million, and the press release states the BBI-940 program will not be advanced
CEO Zachary Hornby steps down July 1, 2026; Chief Legal Officer Jessica Oien to serve as principal executive officer; closing expected in Q4 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.